Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pulse Biosciences CS (PLSE)

Pulse Biosciences CS (PLSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,230,601
  • Shares Outstanding, K 67,989
  • Annual Sales, $ 350 K
  • Annual Income, $ -72,780 K
  • EBIT $ -77 M
  • EBITDA $ -76 M
  • 60-Month Beta 1.74
  • Price/Sales 3,486.86
  • Price/Cash Flow N/A
  • Price/Book 15.10

Options Overview Details

View History
  • Implied Volatility 162.41% (+13.65%)
  • Historical Volatility 150.44%
  • IV Percentile 68%
  • IV Rank 29.34%
  • IV High 352.51% on 11/20/25
  • IV Low 83.46% on 07/29/25
  • Expected Move (DTE 15) 2.47 (13.10%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 136
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 1,978
  • Open Int (30-Day) 1,814
  • Expected Range 16.35 to 21.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.32
  • Number of Estimates 1
  • High Estimate -0.32
  • Low Estimate -0.32
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -28.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.61 +26.66%
on 02/06/26
26.30 -29.64%
on 02/11/26
+4.81 (+35.17%)
since 02/05/26
3-Month
13.17 +40.51%
on 01/02/26
26.30 -29.64%
on 02/11/26
+5.23 (+39.45%)
since 12/05/25
52-Week
12.56 +47.33%
on 11/20/25
26.30 -29.64%
on 02/11/26
+0.84 (+4.78%)
since 03/05/25

Most Recent Stories

More News
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans...

PLSE : 18.87 (+4.25%)
Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting

nPulse™ Vybrance™ System for soft tissue ablation, such as benign thyroid ablation, to be highlighted in podium presentation and product theatre presentation

PLSE : 18.87 (+4.25%)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation...

PLSE : 18.87 (+4.25%)
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present...

PLSE : 18.87 (+4.25%)
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates...

PLSE : 18.87 (+4.25%)
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months

PLSE : 18.87 (+4.25%)
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 18.87 (+4.25%)
Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

nPulse Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission

PLSE : 18.87 (+4.25%)
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

HYPR : 1.1100 (+0.91%)
OFIX : 12.53 (-2.64%)
SPNC : 38.45 (unch)
AVNS : 13.63 (-1.80%)
PLSE : 18.87 (+4.25%)
SWAV : 334.75 (-0.02%)
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced...

PLSE : 18.87 (+4.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Pulse Biosciences, Inc. is a medical device company. It is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling. NPES provide effective local tumor control and to initiate an adaptive immune response. The company deploy NPES platform applications...

See More

Key Turning Points

3rd Resistance Point 19.72
2nd Resistance Point 19.33
1st Resistance Point 18.72
Last Price 18.87
1st Support Level 17.72
2nd Support Level 17.33
3rd Support Level 16.72

See More

52-Week High 26.30
Fibonacci 61.8% 21.05
Fibonacci 50% 19.43
Last Price 18.87
Fibonacci 38.2% 17.81
52-Week Low 12.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar